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ABSTRACT 
For years the functional role of noncoding RNAs was greatly underestimated. Whole genome 
RNA sequencing projects that unraveled pervasive transcription emitting from large parts of 
the human genome changed those perspectives and prompted scientists to further look into 
the involvement of noncoding RNAs (ncRNAs) in development and disease. To date, we 
have significantly advanced our understanding of ncRNAs, however only a fraction of them 
has been functionally characterized. The subject of this thesis is to investigate the functional 
role of long noncoding RNAs (lncRNAs) and their involvement in cancer, particularly in 
cutaneous malignant melanoma.   
Previously, the tumor suppressor gene PTEN has been reported to be post-transcriptionally 
regulated by its pseudogene. In paper I, we investigated an antisense RNA (PTENpg1 
asRNA) that is transcribed from the PTEN pseudogene (PTENpg1). We uncovered various 
PTENpg1 asRNA isoforms and designated two of them as α and β. The role of the PTENpg1 
asRNA β isoform is to form an RNA:RNA duplex with the PTENpg1 transcript. This 
interaction stabilizes and assists the PTENpg1 transcript out to the cytoplasm. On the other 
hand, the PTENpg1 asRNA α has a very different function, namely mediating epigenetic 
changes by recruiting EZH2 and DNMT3a to the PTEN promoter.  
In paper II, we further sought out to understand the recruitment of PTENpg1 asRNA α to the 
PTEN promoter. We observed promoter-associated/5´UTR transcript emitting from PTEN, 
which binds and facilitates the recruitment of PTENpg1 asRNA α to the PTEN promoter. In 
return, PTENpg1 asRNA recruits DNMT3a to the promoter, which leads to epigenetic 
silencing of PTEN.  
In paper III we investigated the role of PTENpg1 asRNA in vemurafenib resistance of 
melanoma. We observed increased PTENpg1 asRNA expression and consequently low PTEN 
levels caused by enrichment of EZH2 and H3K27me3 at the PTEN promoter. Further, we 
found that C/EBPβ transcriptionally induced PTENpg1 asRNA in vemurafenib-resistant 
melanoma cell lines. In addition, manipulation of key components of the PTENpg1 asRNA 
network caused re-sensitization of the resistant melanoma cells to vemurafenib, and high 
PTENpg1 asRNA expression was found to correlate with shorter survival in melanoma 
patients.  
In paper IV, we investigated the effect of the C/EBPβ antisense (C/EBPβ-AS) transcript on 
transcriptional regulation of C/EBPβ. We found that C/EBPβ auto-regulates its own and also 
regulates C/EBPβ-AS expression. In return, C/EBPβ-AS inhibits C/EBPβ positive feedback 
loop by modulating epigenetic changes at the C/EBPβ promoter in melanoma cell lines. 
Interestingly, knockdown of C/EBPβ-AS caused re-sensitization to vemurafenib. 
This thesis highlights the dynamics of lncRNAs in epigenetic silencing and their involvement 
in cancer and therapy resistance.  
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INTRODUCTION 
The existence of an “RNA world” suggesting that life was solely based on RNAs had 
emerged long before sequencing of the human genome1. In spite of strong evidence for 
central role of RNAs in early life it was generally believed that RNAs in humans were merely 
intermediates between DNA and proteins. This dogma, however, changed when human 
sequencing projects reported that about 80% of the human genome was transcribed and only 
less than 1% of these transcripts would give rise to proteins2,3.  This contradicted previous 
presumptions about the vast majority of the genome to be inert and not transcribed4,5.  
In the 50s, the role of the very abundant ribosomal RNAs and transfer RNAs in protein 
synthesis became evident6. Although there has been evidence for other functional RNAs over 
the years, they received relatively little attention. In recent years publications about the 
function of noncoding RNAs (ncRNAs) have been accumulating providing us with a 
completely new insight into their complex regulatory functions. These publications have 
reported on various types of ncRNAs that participate in wide variety of physiological and 
developmental functions. One of the most well described groups of ncRNA is microRNAs 
(miRNAs), which can largely affect gene expression through a variety of mechanisms. 
Another emerging group of ncRNAs is long noncoding RNA (lncRNA) and their functions in 
regulating molecular processes are being gradually discovered.   
One of the great surprises in the field of lncRNAs is the discovery of their role in the 
regulation of epigenetic processes7.  Chromatin-modifying proteins can alter chromatin states 
and influence gene expression and lncRNAs have been shown to bind these proteins and 
guide them to gene specific loci8-10.  
Studies of lncRNAs are not only important for our understanding of the fundamental 
biological pathways, but also, and importantly, to understand and to seek cure of human 
diseases. In this thesis I pursue to understand functional roles of lncRNAs and their roles in 
cancer development and progression 
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BACKGROUND 
In February 2001, the human genome sequence was published “head to head” by two 
different groups. They showed that the human genome comprises of approximately 30,000 
genes and sequence similarities between individuals to be 99.9%11,12. Interestingly, a year 
later it was reported that the homology between mouse genes and humans was almost 
identical13. This was paradoxical to former belief that our genomes should reflect the 
superiority of humans, as proposed by Comings in 1972:  “Being a little chauvinistic toward 
our own species, we like to think that man is surely one of the most complicated species on 
earth and thus needs just about the maximum number of genes”14.  
These recent exploratory efforts greatly extended our knowledge of our genomes. However, 
the human genome project only sequenced euchromatin. At this time it was common 
conception that ncRNAs were “junk” that our genome had accumulated throughout 
evolution. In spite of few reports revealing the biological function of ncRNAs, it has taken 
decades for ncRNA to gain recognition in the scientific community. The exception was 
transfer RNA and ribosomal RNA discovered in 1950 and also a few decades ago there were 
reports about functional RNAs, including RNAse P, small nuclear RNAs (snRNAs) and a 
RNA component of the signal recognition particle, 7SL 15. In the 90s, the ncRNA X-inactive 
specific transcript (Xist) was discovered. Xist mediates the inactivation process of the X 
chromosome in placental mammals16,17. This was considered the exception rather than the 
rule due to the unique early developmental functions carried out by XIST in shutting down 
activity of a whole chromosome.  
The transcriptional complexity and the landscape of the mouse and human genomes were 
elucidated by major sequencing efforts performed by the FANTOM (Functional Annotation 
Of Mouse) and the ENCODE (Encyclopedia of DNA elements) consortia. The backbone of 
the FANTOM projects is a technique called the CAGE (cap-analysis of gene expression) 
technique, which captures 5´capped RNAs transcribed by RNA polymerase II (polII)18. By 
using this technique, the FANTOM3 project showed that majority of the mouse genome is 
transcribed and the coverage of the transcripts is about 62.5% of the genome3.  The aim of the 
ENCODE project was to explore and annotate all functional elements of the human genome 
by using high-throughput methods. The first pilot phase of the ENCODE project indicated a 
lot of pervasive transcription19 and later they showed that approximately 60-75% of the 
human genome is transcribed into RNAs while only 1% will code for proteins20. It had 
become increasingly difficult to overlook all of the pervasive transcription in the human 
genome and the fact that non-coding transcripts in humans exceeds other species21. So maybe 
after all humans are more complex than other species. To date, predicted protein-coding 
genes in humans are estimated around 20,000 and lncRNAs are thought to account for about 
10,00022. This prediction might however be underestimated. For example, one recent study 
overlaid RNA sequencing libraries from cell lines, tumor and normal tissues that showed that 
68% of the transcribed genes were lncRNAs and 79% of them were previously 
unannotated23. A plausible explanation for the discrepancy is the fact that lncRNAs are often 
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expressed at rather low levels in a tissue specific manner. Therefore, the number of expressed 
lncRNAs could increase in the future due to emerging deeper sequencing techniques and by 
exploring early embryonic stages. Taken together, it has become evident that cells produce 
large amount of lncRNAs. However, only a tiny fraction of these lncRNAs have been 
functionally characterized.  Therefore, increased functional studies of lncRNAs could aid in 
understanding the onset and progression of various human diseases.  
1.1 CANCER  
The World Health Organization estimated 14.1 million new cancer cases worldwide in 2012 
and annual rates are expected to rise to 19.3 million before the year 202524. Factors, such as 
longevity, cancer screening programs and better diagnostics, can greatly contribute to the 
growing cancer incidence rates. Along with growing incidence, the efforts from academic 
research and pharmaceutical industries result in the introduction of novel and effective 
treatment modalities against cancer. In spite of these advances in cancer therapy, drug 
resistance remains one of the major obstacles in cancer treatment.   
Cancer is a heterogeneous disease with common characteristic of abnormal cell growth that 
goes beyond its boundaries. In 2000 Hanahan and Weinberg described six major hallmarks of 
cancer: (i) self sufficiency in growth signals, (ii) evading apoptosis, (iii) sustained 
angiogenesis, (iv) limitless replication potential, (v) insensitivity to anti-growth signals and, 
(vi) activating invasion and metastasis25.  Eleven years later the same authors added tumor 
microenvironment to the hallmarks of cancer26. Interestingly, lncRNA have been shown to be 
involved in all of these fundamental elements that contribute to tumor development27 (Figure 
1). 
 
Figure 1 The hallmarks of cancer and an example of a lncRNA involved in each of the hallmarks (modified 
from28). 
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1.1.1 Cutaneous malignant melanoma  
Melanoma is a malignant tumor that originates in melanocytes and commonly arises on the 
skin surface29. Although cutaneous malignant melanoma (CMM) account for only 5% of skin 
cancer, it causes 75% of all skin cancer-related deaths. Risk factors for melanomas are 
increased numbers of melanocytic nevi, light skin, hair and eye color and ultraviolet light 
(UV) exposure29. Only about 6-12% of new cases of CMM are family related, often carrying 
a germline mutations in the CDKN2A gene30. Other genetic predisposition that increase the 
lifetime risk of acquiring melanoma are loss of function of the cyclin-dependent kinase 4 
(CDK4), mutations in the tumor suppressor RB1 and missense substitution of the 
transcription factor MITF30-32. Somatic mutations contributing to melanomagenesis have been 
reported.  The most common somatic deviations are mutations in the BRAF gene (66%) and 
NRAS (20%), which lead to activation of the mitogen-activated protein kinase (MAPK) 
pathway that stimulates cell growth and survival33,34. Although not as common as BRAF and 
NRAS mutations, KIT mutations are found in a small subset of patients (1%)35. Recently, 
these findings have led to the discovery of small molecule inhibitors that target the mutated 
forms of BRAF and KIT. The role of BRAF and BRAF inhibitors are described in more 
details in section 1.2.2.    
Tumor progression of melanocytes into advanced metastatic cancer occurs in 5 steps:  
Step 1. Common acquired nevus  
Step 2. Dysplastic nevi (has architectural and cytological atypia)  
Step 3. Radial growth phase (dysplastic lesions start to form) 
Step 4. Vertical growth phase (higher risk for metastasis)  
Step 5. Metastatic melanoma36 
Patients who have their tumors detected at early stages of melanoma progression will have 
increased cure rates and good prognosis. Unfortunately, for those patients diagnosed with 
advanced metastatic melanoma, the median survival time is only 6-9 months and the cancer 
has become incurable37. For these patients chemotherapy results most often in partial 
responses with response rates as low as 5-12%38 and radiotherapy is mainly used as palliative 
therapy39.  Thus, detection and prevention of melanomas are a crucial part in fighting this 
disease. However, recent advances in drug development of small molecule inhibitors have 
brought some hope for metastatic melanoma patients.  
1.1.2 LncRNA in melanoma 
At least dozen of lncRNAs have been reported to participate in the pathogenesis of cutaneous 
melanoma, among those are HOTAIR, MALAT1, ANRIL and GAS528. A study reported 
deregulation of ~100 lncRNAs upon induced expression of BRAFV600E. In this screen the 
lncRNA BANCR (BRAF-activated non-coding RNA) was discovered and shown to influence 
gene expression in trans of genes involved in cell migration40. Further, knockdown of 
BANCR resulted in disruption of proliferation in melanoma cell lines and high BANCR 
expression levels were correlated with shorter patients survival41, suggesting its pro-
oncogenic functions in melanoma. Another pro-oncogenic lncRNA called SAMMSON was 
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found in 90% of melanomas. SAMMSON is frequently co-amplified with the transcription 
factor MITF but appears to function independent of MITF. SAMMSON transcription is driven 
by the lineage-specific transcription factor SOX10, and was shown to drive mitochondrial 
function in melanoma. Targeting of SAMMSON sensitized melanoma to MAPK-targeting 
therapeutics42, indicating SAMMSON as a potential therapeutic target. The role of PTEN 
pseudogene acting as a miRNA sponge (see chapter 1.4.1) has also been suggested to 
contribute to the development and progression of melanoma43,44. Interestingly, the PTEN 
pseudogene has been shown to be deleted in ~14-21% of melanoma43, indicating a possible 
role in cancer development.  
1.2 TUMOR SUPPRESSIOR GENES AND ONCOGENES 
Tumor suppressor genes and oncogenes are two classes of genes that can drive tumor 
development and progression, either through their inactivation (tumor suppressor genes) or 
an illegitimate activation (oncogenes). Loss of function of tumor suppressor genes can 
occur through e.g. mutations, chromosomal rearrangements or epigenetic silencing, while 
an overexpression due to mutations, chromosomal translocations, or an abnormal signaling 
can lead to activation of oncogenes.  
In general, Knudson´s “two hit hypothesis” applies to tumor suppressor genes. Knudson´s 
hypothesis suggests that tumor suppressor genes loose their function if both alleles become 
inactive by two mutational events45. There are exceptions to this rule where tumor 
suppressor genes can also loose their function through epigenetic changes or 
haploinsufficiency46.  The very well studied TP53 gene is an example of tumor suppressor 
gene and has the highest mutation rates in human cancer47.  P53 has a diverse function but 
is mostly known for its ability to induce cell cycle arrest and apoptosis48. BRCA1 and 
BRCA2 genes are also good examples of tumor suppressor genes. The BRCA genes play an 
important role in error-free DNA damage repair. Inherited mutations in the BRCA genes 
greatly increase the risk of breast, ovarian and prostate cancer49-52.  
The oncogene Src was the first oncogene discovered in chicken retrovirus53. Since then 
numerous oncogenes have been discovered. Another example of an oncogene is the 
transcription factor MYC that is frequently amplified in human cancers. Aberrant 
expression of the proto-oncogene MYC results in transcriptional deregulation of many 
genes and is known for its role in genomic instability54. In humans three RAS genes are 
found (NRAS, KRAS and HRAS) and all have been shown to be oncogenic in various types 
of cancer55. RAS proteins are GTPases and oncogenic mutations in RAS genes result in a 
constitutively active protein leading to activation of RAS downstream targets in the PI3K-
AKT-mTOR and Raf-MEK pathways56. 
Taken together, tumor suppressors and oncogenes play a major part in tumorigenesis and 
tumor progression. Here, the tumor suppressor PTEN and the oncogene BRAF will be 
discussed in more details below.   
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1.2.1 PTEN  
Early genetic studies revealed a partial or full loss of chromosome 10 in brain, bladder and 
prostate cancers57. Later PTEN (Phosphatase and tensin homolog) was mapped to 
chromosome 10 and germline mutations in PTEN were found in patients with cancer 
predisposition syndromes (e.g. Cowden disease)58,59. In addition, PTEN was often found to be 
dysregulated in various tumor types and PTEN knockout mice were shown to be prone to 
tumor formations58,60. These initial studies confirmed the tumor suppressor activity of PTEN. 
Interestingly, for PTEN, Knudson´t two hit model does not apply because subtle 
downregulation of PTEN levels can promote cancer susceptibility61. Therefore, PTEN needs 
to be maintained at stable levels in order to avoid tumorigenesis, which implies a necessity 
for a tight regulation of PTEN expression. PTEN levels can be regulated transcriptionally, 
post-transcriptionally and post-translationally. The tumor suppressor p53, early growth 
response protein 1 (EGR-1) and peroxisome proliferator-activated receptor γ (PPAR-γ) have 
all been found to be positive regulators of PTEN by binding to the PTEN promoter to activate 
PTEN transcription62-64. PTEN has also been shown to be negatively regulated by the 
transcription factor c-Jun that can bind to the 5´upstream sequence of PTEN and inhibit its 
transcription65. Furthermore, epigenetic remodelers can contribute to transcription of PTEN 
and epigenetic silencing at the PTEN promoter is seen in various types of cancer, including 
melanomas 66-68. PTEN is also regulated post-transcriptionally by plethora of miRNAs that 
bind to the 3´UTR of PTEN mRNA and cause degradation of the mRNA or translational 
repression69-72. Excessive amount of particular miRNAs that target PTEN can therefore 
contribute to tumorigenesis through lowering PTEN levels73. Phosphorylation, oxidation, 
acetylation and ubiquitination can all affect PTEN at the post-translational level. These 
alterations can change the localization or the stability of PTEN, in addition to interfering with 
PTEN protein interactions74-78.   
The main catalytic function of this phosphatase is to generate the inactive form PIP2 
(Phosphatidylinositol 4,5-bisphosphate) by dephosphorylation of PIP3 (also known as 
PtdIns(3,4,5)P). Typically, the PI3K (phosphatidylinositol-4,5-bisphosphate 3-kinase) are 
activated by stimuli (hormones, growth factors, chemokines or cytokines) that bind and 
signal through receptor kinases or G proteins coupled receptors (GPCRs)79. PI3K generates 
the phospholipid PIP3 by phosphorylating the 3-postion of the inositol ring of PIP280.  PIP3 is 
localized to the cellular inner membrane and recruits and activates PDK (3-phosphoinositide-
dependent kinase) and AKT (protein kinase B)81.  AKT is activated by phosphorylation at 
two different residues Thr308 and Ser47382. Active AKT leads to cascade activation of 
various proteins that drive cell survival, cell proliferation, angiogenesis and cellular 
metabolism82.  Loss of PTEN will therefore lead to constitutively active PI3K-AKT-mTOR 
pathway and promote cell growth and survival83 (Figure 2).   
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Figure 2 The PI3K/AKT pathway. Upon stimuli, a receptor tyrosine kinase (RTK) activates PI3K kinase, which 
catalyzes phosphorylation of PIP2 into PIP3. PIP3 then recruits and activates PDK and AKT. PTEN antagonizes 
the PI3K/AKT pathway by dephosphorylating PIP3.  
1.2.2 BRAF  
Activating mutations in the serine/threonine kinase BRAF (v-Raf murine sarcoma viral 
oncogene homolog B) are found in 8% of human tumors and the highest BRAF mutation 
incidence is observed in melanoma (27-67%)34. Various BRAF mutations have been reported 
that lead to elevated kinase activity; of which, the most common mutation is the glutamic 
acid substitution for valine at codon 600 (V600E)34,84. Interestingly, BRAFV600E is found 
in 80% of benign nevi, implying that BRAF mutation is not sufficient to induce melanoma 
and additional molecular event(s) are required for the tumorigenesis85. However, 
BRAFV600E expression in nude-mice leads to an increased ability for non-transformed 
melanocytes to form tumors86 and BRAFV600E inhibition in xenograft models induces 
growth arrest and apoptosis87,88.  
BRAF is a part of the RAS/RAF/MEK/ERK signaling pathway (or MAPK pathway) that 
controls cell proliferation, survival, senescence and differentiation in melanoma89. RAS 
(HRAS, KRAS and NRAS), RAF (ARAF, BRAF, CRAF), MEK (MEK1, MEK2) and 
ERK (ERK1, ERK2) proteins are key components of the MAPK pathway. Generally, the 
upstream signal for activation of RAS proteins are generated by extracellular signals and 
activation of receptor tyrosine kinases90. This leads to the formation of active RAS-GTP 
complexes from the inactive form RAS-GDP. RAS-GTP mediates phosphorylation and 
activation of BRAF that promotes its homodimerization91. BRAF homodimers 
phosphorylate MEK, which in return phosphorylate and activate ERK92. The active ERK-
regulated transcription factors activate transcription of genes leading to cell proliferation. 
ERK also induces a negative feedback in the MAPK pathway, by inhibiting 
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phosphorylation of RAS through inhibition of receptor tyrosine kinases and de-
phosphorylation of BRAF93,94.  
BRAFV600E inhibitors  
Treatment options for melanoma patients largely depend on the stage of the disease at 
diagnosis. Although surgical excision is sufficient in early stages of melanoma, the 
therapeutic options for advanced diseases are limited due to the fact that chemotherapy and 
radiation have not shown to be a great success. Recently, small molecule inhibitors have been 
developed and shown to be effective in melanoma patients that carry activating mutations in 
BRAF. Vemurafenib and dabrafenib are examples of BRAF inhibitors, and 80% of patients 
with advanced melanoma carrying a BRAFV600E mutation initially respond well to 
vemurafenib treatment and show tumor regression95. At the time of the discovery, this drug 
attracted a broad attention and raised hopes for effective melanoma treatment. However, it 
also brought a deep disappointment since the vast majority of patients developed resistance to 
vemurafenib, which typically emerged within 6-7 months of treatment96. In recent years, 
efforts have been made to understand the molecular mechanisms underlying the acquired 
vemurafenib resistance97,98 Constitutively active PI3K/AKT pathway, due to loss of PTEN, 
has been shown to be one of the mechanisms contributing to vemurafenib resistance99 (Figure 
3). Mutational activation in NRAS is also commonly seen in vemurafenib resistance100. This 
activation leads to increased formation of RAF hetero- or homodimers consequently causing 
activation of MEK. Secondary mutations in MEK leading to activation of the MAPK 
pathway are also found in vemurafenib-resistant melanomas101. Another scenario of 
vemurafenib resistance is activation of the serine/threonine kinase COT (Cancer Osaka 
Thyroid oncogene, also known as MAP3K8) that can activate ERK but does not require 
RAF102. 
 
Figure 3 A Schematic depicting how loss of PTEN can contribute to vemurafenib resistance. BRAFV600E leads to 
hyperactive MEK/ERK signaling pathway without involvement of upstream signaling. Vemurafenib targets 
BRAFV600E and shuts down the MEK/ERK signaling pathway. Upon vemurafenib resistance the MEK/ERK 
signaling pathway is restored as well as the PI3K/AKT pathway is activated due to loss of PTEN to promote cell 
proliferation and survival.   
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1.2.3 C/EBPβ  
Although C/EBPβ (CCAAT/enhancer-binding protein β)  has not been titled as an oncogene 
or a tumor suppressor, it has been shown to be implicated in various types of cancers 
(reviewed in 103). Therefore this gene will be included in this chapter.  
C/EBPβ is a versatile transcription factor (TF) that can carry out multiple cellular functions, 
such as cell proliferation, differentiation and senescence. This protein is a part of the basic 
leucine zipper (bZIP) transcription factor family, which consists of two domains: DNA 
binding domain and multimerization domain104. Commonly, C/EBPβ will homodimerize or 
heterodimerize to other proteins from the C/EBP family. C/EBPβ binds double-stranded 
DNA in a sequence specific manner through the consensus sequence, RTTGCGYAAY 
(R=A/G, Y=C/T)105, however different binding motifs for C/EBPβ have also been 
reported106.  
C/EBPβ is translated to three different isoforms, i.e. two long isoforms (LAP1 and LAP2) 
and one short isoform (LIP)107. The proportion between them is important for the cell to 
maintain normal growth and development108.  The isoforms have been shown to be capable of 
carrying out different functions. For example, the LAP1 has been shown to recruit the SWI-
SNF nucleosome remodeling complex to silence genes, which leads to increased access of 
TFs to DNA through chromatin remodeling109.  Different isoforms of C/EBPβ can also bind 
to their specific promoters, e.g. only LAP2 can bind to the Cyclin D1 promoter 110.  
Although methylation of CpG islands is commonly correlated with repressed transcription, 
there is recent evidence showing that some DNA methylated sites can have increased TF 
binding and induced gene activity111-113. For example, the promoter region of FOXA2 gene 
shows high DNA methylation levels in tissue that express FOXA2111. CEBPβ has been 
reported to show enhanced binding affinity towards methylated promoters and/or CpG 
islands, in particular the CRE (cAMP response elements) and C/EBP motifs, leading to 
increased gene activity114,115. 
Dysregulation of C/EBPβ plays a role in tumorigenesis. In primary human and mouse 
fibroblasts that express oncogenic RAS or BRAF, C/EBPβ has been shown to guard RAS- 
and BRAF-mutated cells from cellular transformation by inhibiting cell proliferation and 
inducing senescence116,117. Therefore, bypassing the C/EBPβ activity is necessary for 
continued cell proliferation and several mechanisms of how this occurs have been 
suggested118. On the contrary, CEBPβ expression was found to be essential for formation of 
skin tumors in the majority of tumors carrying Ras mutations119. Additionally, high C/EBPβ 
expression can also contribute to tumorigenesis. For example, C/EBPβ has been shown to 
be overexpressed at late stages of breast carcinogenesis120 and induce epithelial-to-
mesenchymal transition in mammary epithelial cells121. C/EBPβ can also regulate 
metastatic genes and survival in prostate cancer cells122,123 and mesenchymal 
transformation in human gliomas124. A better knowledge of CEBPβ contribution to 
tumorigenesis is needed to understand if CEBPβ could represent a promising drug target.  
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1.3 NONCODING RNA 
Noncoding RNAs are grouped into small (<200 nucleotides (nt)) or long noncoding RNAs 
(>200 nt). This arbitrary classification is originally based on the Qiagen RNA isolation kit 
that will keep long RNAs while short RNAs will filter through125. 
1.3.1 Long noncoding RNA 
LncRNAs represent a large proportion of transcripts found in the human genome. To some 
extent lncRNA resemble messenger RNAs (mRNAs), by often being 5´capped, 
polyadenylated, spliced and transcribed by RNA pol II126. However, unlike protein coding 
genes many of these lncRNAs lack sequence conservation between species and therefore the 
hypothesis has been that lncRNAs simply represent transcriptional noise. Indeed only 20% of 
lncRNA show an inter-species homology between human and mouse and this proportion is 
even lower, about 5%, for homology between humans and fish127. It is, however, important to 
keep in mind that although sequence conservation usually implies functionality, lack of 
conservation does not necessarily imply the opposite128. Also, the conserved function of 
RNAs between species could occur through secondary structures, which are not based on 
exact homology but nevertheless are important for RNA functions; at least this feature has 
been demonstrated for small non-coding RNA, like tRNA and snoRNAs. Studies on 
lncRNAs secondary structures are however scarce and difficult to carry out due to a steady 
uncertainty in the predicting models. Triplex elements are one of the few structures that have 
been reported to stabilize the 3´ends of the lncRNAs, MALAT1 (metastasis-associated lung 
andenocarcinoma) and MEN β, that both lack a poly-A tail129.  Another evolutionarily 
conserved domain is the tandem stem-loops in roX1 and roX2 RNAs in D. melanogaster that 
has been found to bind the MLE RNA helicase and the MSL2 ubiquitin ligase to mediate X-
chromosome dosage compensation130. Recently the secondary structure of HOTAIR was 
published and notably some secondary structure elements within HOTAIR structure are 
conserved across 33 mammalian sequences131. However, a contradicting study claim that 
lncRNAs, including HOTAIR, do not have a conserved structure132. In addition to sequence 
and structure, functional conservation could also be obtained through the position of 
lncRNAs within a genome: thus the location of antisense transcripts may play an important 
role in regulating their sense counterpart133.  
Functional characterizations of lncRNAs are still in its infancy. One important aspect to 
reveal their specialized function is subcellular localization of lncRNAs. LncRNAs localized 
in the nucleus often act as epigenetic modulators (Figure 4A-B), while those in the cytoplasm 
often have post-transcriptional functions (reviewed in 134).  For example, the lncRNA NRON 
regulates trafficking of the transcription factor NFAT into the nucleus135 and the lncRNA 
SNHG5 stabilizes the mRNA SPATS2 by forming a RNA:RNA duplex making the mRNA 
inaccessible to the destabilizing protein, STAU1 lncRNAs  (Figure 4F-E)136,137.  
One might speculate that the nuclear lncRNAs are kept in the nucleus by interacting with 
proteins that facilitate their subcellular localization (Figure A-C). For example, the matrix 
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protein hnRNP U regulates localization of the lncRNAs XIST and FIRRE to specific 
chromosomal loci and knockdown of hnRNP U leads to their mislocalization138,139. In 
addition, lncRNAs could be kept in the nucleus by binding to protein complexes, such as 
PRC2, preventing them from exiting to the cytoplasm (reviewed in 140). Generally, it is 
assumed that processed lncRNAs will be exported to the cytoplasm in a similar manner as 
mRNAs, however this remains to be experimentally tested (reviewed in140).  
 
Figure 4 Functions of lncRNAs. (A-B) LncRNA recruit epigenetic modifying proteins to chromatin. (C) 
LncRNA can act as decoy keeping proteins away from the DNA. (D) LncRNA can act as scaffolds pulling 
proteins together. (E) LncRNA (and ciRNA) can act as miRNA sponges. (F) LncRNA can block accessibility of 
RNA degradation proteins by forming RNA:mRNA duplexes.  
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Although the subcellular localization of a lncRNA can help predict its function, lncRNAs are 
currently classified according to their genomic location and relation to protein coding genes. 
The main subclasses of lncRNA (Figure 5) are22:  
• Antisense RNA (asRNA) 
• Large intergenic RNA (lincRNA) 
• Sense overlapping RNA 
• Sense intronic RNA 
• Processed transcripts (without an open reading frame (ORF) and does not fit in of 
the other categories) 
• Trancribed psuedogenes141 
There are other subgroups of RNA that are emerging, for example enhancer RNA (eRNA) 
and circular RNA (ciRNA) but they coincide in part with other subgroups of ncRNAs. 
LincRNAs is the most abundant class of lncRNAs and their expression is highly tissue 
specific142. Although not as common as lincRNAs, antisense RNAs that overlap their sense 
counterparts will be discussed here in greater details.     
 
Figure 5:  A schematic depicting the main subclasses of lncRNAs. (A) Antisense RNA (B) LincRNA (C) Sense-
intronic RNA (D) Sense-overlapping RNA   
1.3.2 Cis-acting lncRNA with focus on antisense RNA 
First reports from the FANTOM consortium suggested that about 20% of transcribed genes 
have an antisense transcription143. Later, the FANTOM3 project and other groups reported 
that antisense transcripts are emitting from about 2/3 of protein-coding genes in the 
mammalian genome3,144.  Antisense RNAs arise from the same genomic loci as their sense 
counterpart but are transcribed from the opposite DNA strand. They may be coding or 
noncoding RNA complements. The orientation of antisense RNA towards its sense 
counterpart is described as being “head to head” or “tail to tail”. There are also transcripts that 
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have full overlaps and antisense transcripts that are only nearby the head or the tail and 
therefore literally do not overlap. Antisense transcripts can act in cis or in trans. Cis-antisense 
RNAs interact with genes at the same genome loci while trans-antisense RNAs interact with 
distant genes on the same chromosome or genes on different chromosomes 145. Cis- acting 
lncRNA can influence gene expression of overlapping gene counterpart or a gene that has a 
proximal location towards the lncRNA. The following are a few examples of cis regulatory 
lncRNAs.    
X-chromosomal inactivation   
In spite of low gene density on the X-chromosome, inactivation of one X-chromosome is 
vital in eutherian females to compensate for gene dosage imbalance between sexes. 
LncRNAs are key players in X-chromosomal inactivation (XCI) and the X inactivate specific 
transcript (Xist) is one of the most extensively studied lncRNA. Xist is a nucleus-localized 
lncRNA transcribed from the X-inactivation center (Xic) and physically coats the inactive X-
chromosome16,17,146. Xist is 17 kilobases (kb) with several tandem repeats, however only one 
of the repeats located in the 5´end is relatively well conserved and thought to be critical for 
Xist function146,147. Xist orchestrates along with other lncRNAs a cascade of chromatin 
changes that lead to transcriptional silencing of the X-chromosome that is destined to be 
inactive, by modification of core histones through acetylation or methylation and exclusion of 
RNA polymerase II 148. 
Xist has a 40 kb antisense transcript called Tsix that prevents Xist to be transcribed from the 
active X-chromosome149. Before the onset of X-chromosomal inactivation, Tsix is expressed 
from both X chromosomes, however, after the process has been initiated Tsix is only 
transcribed from the active chromosome149. Thus, on the inactive chromosome where Tsix is 
not expressed Xist will accumulate.  It is believed that Tsix blocks the XCI by interacting with 
the polycomb repressor complex 2 (PRC2) but instead of recruiting it to the XCI it sequesters 
PRC2 away from Xist and inhibits their interactions150. Interestingly, Tsix has also been 
shown to interact with DNA methyltransferase 3a (DNMT3a), which are known to methylate 
gene promoters leading to epigenetic silencing. When this interaction was abolished 
DNMT3a was not recruited to the promoter of Xist151 and thus could not DNA methylate the 
promoter leading to transcriptional activation of Xist. 
JPX is another lncRNA involved in X chromosomal inactivation. The transcription factor 
CTCF (CCCTC-binding factor) represses Xist transcription prior to the XCI; however, after 
initiation of XCI, JPX becomes upregulated and binds to CTCF and titrates it away from the 
Xist promoter leading to Xist expression152.  
The complexity of the involvement of lncRNAs in XCI is a good example of the many 
facades of the functional role lncRNAs and the importance of the tight transcriptional 
regulation executed by lncRNAs.  
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Airn (Insulin-like growth factor 2 receptor (Igf2r) lncRNA) 
The imprinted Igf2r gene is important in fetal and placenta development153,154.  The IGF2 
receptor has a role in binding to the major fetal growth factor IGF2 and target it for lysosomal 
degradation155.  The Igf2r gene has two differentially methylated regions: one is located at the 
promoter and the other in intron 2 of Igf2r gene. This latter region is a promoter for an 
asRNA named Airn (antisense Insulin–like growth factor receptor). In mice, Airn is 
paternally expressed lncRNA that acts in cis by mediating transcriptional silencing of 
Igf2r156,157. Previous speculation of the mechanism of Airn suggested that Airn mediates 
silencing of Igf2r through recruitment of epigenetic proteins to Igf2r promoter158. However, 
more recent studies claim that Airn transcription will interfere with RNA pol II and thereby 
block the capacity to transcribe Igf2159. Interestingly, a human homolog for Airn is 
transcribed from the same genomic loci as in mice but has not been shown to be involved in 
imprinting of IGF2R and therefore has an undescribed role in humans159.  
ANRIL (antisense noncoding RNA in the INK4 locus) 
In the INK4b/ARF/INK4a locus resides three possible tumor suppressor genes 
p15/CDKN2B, p16/CDKN2A and p14/ARF160, and they are under tight regulation of the 
polycomb group complex161. ANRIL is a large antisense RNA overlapping the 
INK4b/ARF/INK4a locus and was first discovered in a melanoma-neural system tumor 
family162. ANRIL is expressed from the proximal promoter of INK4a and encodes for a 125 
kb long transcript162. ANRIL binds to chromobox protein homolog 7 (CBX7), a subunit of the 
polycomb repressive complex 1 (PRC1), and together they mediate silencing at the 
INK4/ARF locus163. ANRIL has shown to have multiple isoforms and that some of them can 
form circular RNAs164.  Interestingly, one circANRIL was shown to modulate ribosomal 
RNA maturation by binding to a 60S pre ribosomal assembly factor and inhibiting 
exonucleases mediated processing165,166. Furthermore, ANRIL can also function in trans by 
modulating various gene expression networks167. ANRIL´s different isoforms and functions is 
a good example of how transcriptional complexity can contribute to different functions.  
WRAP53 
Interestingly, p53 itself is regulated by an antisense transcript, WRAP53α, encoded by the 
WRAP53 gene that overlaps the p53 gene in a “head-to head” orientation. In this case, 
WRAP53α RNA interacts with the complementary region of p53 RNA and thereby 
stabilizes p53 RNA. Disruption of this interaction by knocking down WRAP53α or blocking 
the WRAP53α/p53 hybrids leads to decreased p53 RNA levels168. Moreover, WRAP53α 
RNA was found to interact with the CTCF important for the transcriptional regulation of p53 
RNA expression 169.  
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1.3.3 Trans-acting lncRNA 
LncRNA that directly influence gene expression on different chromosomes are trans-acting 
lncRNAs. HOTAIR was the first lncRNA that was reported to function in trans. Since then a 
number of publications have observed this phenomenon as a mechanism of action of a variety 
of lncRNAs.   
HOTAIR (Hox transcript antisense intergenic RNA) 
In the human genome there are 39 genes that encode for HOX transcription factors. They all 
reside within four different loci, HOXA-HOXD. One of the best studied lncRNA, HOX 
transcript antisense intergenic RNA (HOTAIR), resides within the HOXC locus and 
functions in trans by mediating gene silencing covering 40 kb of the HOXD locus. HOTAIR 
is a 2.2 kilobase (kb) long ncRNA that has two protein binding domains at the 5´ and 3´ end. 
Initial studies showed reduced levels of SUZ12 (a subunit of the epigenetic silencing 
complex PRC2) and H3K27me3 at the HOXD locus after siRNA-mediated knockdown of 
HOTAIR170. Interestingly, no effect on gene expression on the HOXC locus (where the 
HOTAIR gene is located) was observed. Pulldowns using biotinylated HOTAIR show a direct 
interaction with the PRC2 components EZH2 and SUZ12. HOTAIR is therefore thought to 
guide the PRC2 complex to the HOXD locus171. While the PRC2 complex binds to the 
5´domain of HOTAIR, the 3´domain is thought to interact with the histone demethylases, 
LSD1 that is a part of a histone modification complex called CoREST/REST (Figure 4D). 
HOTAIR can therefore acts as a modular scaffold between these two complexes leading to 
transcriptional repression at the HOXD locus172,173. Overexpression of HOTAIR has been 
reported in breast cancer metastasis; an ectopically induced HOTAIR expression in breast 
cancer cell lines lead to cancer cell invasion and promotes colony growth 174.  Since then 
numerous publications have linked HOTAIR expression to cancer-associated processes, such 
as metastasis and tumor invasion as well as to prognosis 175-178.  
MALAT-1 (metastasis associated lung adenocarcinoma transcript 1) 
The ~8 kb long MALAT-1 was one of the first lncRNA that was linked to human cancer and 
metastasis and has been shown to be overexpressed in numerous cancers179,180. Later the 
function of the MALAT-1 was uncovered. MALAT-1 localizes to the nuclear speckles and 
interacts with serine/arginine splicing factors that regulate alternative splicing. The 
interaction between MALAT-1 and these splicing factors influences the distribution of these 
splicing factors in a nuclear speckle domain. Therefore, repressed expression of MALAT-1 
leads to alterations in alternative splicing of endogenous mRNAs181. MALAT-1 has also an 
alternative function where it can interact with a component of the PRC1 complex (CBX4 
(Chromobox homolog 4)) and thereby actively regulate gene expression, including genes 
associated with metastasis182,183.  
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LincRNA-p21 
The lncRNA LincRNA-p21 is regulated by p53 and in return inhibits the expression of 
hundreds of genes that are repressed by p53.  LincRNA-p21 physically interacts with the 
RNA binding protein, hnRNP-K and mediates the localization of this protein to gene loci, 
which consequently leads to transcriptional repression184 . In addition, LincRNA-p21 has an 
alternative function as a modulator of translation. The HuR protein binds to LincRNA-p21 
leading to recruitment of let7/Ago2 and causes instability of LincRNA-p21. In the absence 
of HuR, LincRNA-p21 levels increase, an interaction of LincRNA-p21 with mRNAs is 
induced, in return leading to a lower translation of the mRNA products184. Since the 
discovery of LincRNA-21 numerous publications have reported a link between LincRNA-21 
deregulation and cancer185-187, yet again stressing the importance of lncRNAs in cancer 
development.  
1.3.4 Short ncRNA 
Short ncRNAs have been more extensively studied than lncRNAs. They are classified into 
the following subgroups: microRNAs (miRNAs), small-interfering RNAs (siRNAs), piwi-
interacting RNA (piRNAs), small nucleolar RNAs (snoRNAs), small nuclear RNAs 
(snRNAs), extracellular RNA (exRNAs) and Small Cajal body-specific RNAs (scaRNAs). 
Short ncRNAs are typically between 20-30 nt and are associated with Argonaute (AGO) 
family proteins. MicroRNAs is the group of short ncRNAs has been most extensively studied 
and over 2.000 miRNAs genes have been annotated in humans 188,189.  
1.3.4.1 MicroRNA 
MicroRNAs are generally 20-24 base pairs (bp) in length and bind to mRNAs in a sequence 
specific manner, usually in the 3´ untranslated region (UTR) of mRNAs. Generally, miRNA 
originates from a long primary transcripts transcribed by RNA pol II called primary miRNA 
(pri-miRNA)190. The pri-miRNA contains a stem loop structure that is recognized by the 
nuclear RNase III Drosha that is a part of the microprocessor complex that crops the pri-
miRNA down to a small hairpin structure called pre-miRNA, typically around 70 nt in 
length191. Following Drosha-mediated processing, pre-miRNAs are exported to the cytoplasm 
where another RNase III enzyme called Dicer cleaves of the loop leaving a miRNA 
duplex192,193. Finally, the mature miRNA duplex is loaded onto the AGO protein, which will 
form the RNA induced silencing complex (RISC)194. The miRNA will then serve as a guide 
for the RISC complex to the target mRNA. MiRNA targeting often leads to post-
transcriptional gene silencing, and it has been suggested that about 30-60% of all human 
mRNA are under regulatory roles of miRNAs 195,196.  
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1.3.5 Promoter associated RNA 
Promoter associated RNAs (RNAs) are also known as promoter-proximal transcription start 
site RNAs, promoter upstream transcripts or transcriptional start site-associated RNAs197. 
Deep RNA sequencing and Global Run-on-Sequencing (GRO-seq) lead to the discovery of 
paRNAs, which are most often lowly expressed and unstable transcripts198,199. There are 
three main subgroups to be found, again categorized according to size, tiny, short and long 
paRNAs. Typically, paRNAs are being transcribed in the same direction as their downstream 
genes198,199 but antisense transcription can also occur. They are often associated with highly 
expressed mRNA transcripts and RNA Pol II binding sites200 and thought to modify the 
chromatin state of their corresponding genes’ promoters.  
Tiny paRNAs 
Tiny paRNAs or transcription initiation RNAs (tiRNAs) are typically 18 nt in length and map 
within -60 to +120 nt of transcription start sites (TSSs)200.  They are not Dicer-2-, Ago1- or 
Ago2-dependent in contrast to miRNAs200. Transcription of tiRNAs is often found 
downstream of TSSs and therefore it is thought unlikely that they are products of RNA pol II 
run offs or truncated 5´capped ends200.  A possible hypothesis for how tiRNA are generated is 
that RNA pol II binds to the DNA strand to initiate transcription but does not manage to push 
through the 1st nucleosome and therefore causes pausing or backtracking (reviewed in 201). 
The functionality of tiRNAs is not fully known but they are thought to play a role in 
transcription. For example tiRNAs are frequently found in CTCF binding sites and inhibition 
of tiny paRNAs transcription leads to increased binding of CTCF to the DNA202.   
Short paRNAs 
Short paRNAs are generally between 20-90 nt and originate within -50 bp to +250 bp of the 
TSS198. They have been described to be polyadenylated with a high turnover rate203. In 
embryonic stem (ES) cells short paRNAs have been shown to be lowly expressed transcripts 
found to be bound to chromatin loci that are enriched with RNA Pol II and histone H3 lysine 
4 trimethylated (H3K4me3). Interestingly, short paRNA appear to be fairly common 
phenomenon and are transcribed in more than half of mouse genes. Like tiRNAs, short 
paRNA were found to be Dicer independent in Dicer deficient ES cells198. In humans, the 
expression levels of short paRNAs correlate to mRNA expression levels and promoter 
activity of the corresponding gene198. Short paRNAs are thought to influence gene 
transcription by maintaining an accessible chromatin for TFs, either by releasing negative 
supercoils or keeping a nucleosome-free region at TSSs197. Short paRNA have also been 
reported to act as transcriptional repressors. For example, cells transfected with short paRNA 
that correspond to the c-MYC TSS showed reduced MYC mRNA abundance204. In addition, 
similar to the long paRNAs, short paRNA may also give rise to endo-siRNA 197. 
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Long paRNAs 
Accumulation of unstable long paRNAs, spanning around 250-500 nt, were first noticed in 
yeast that had defects in an exosome component RRP6, which degrades RNA205. Although 
long paRNAs have not been thoroughly studied they are thought to influence DNA 
methylation. For an example, the Sphk1 gene has an antisense transcript that emits from the 
CpG island at its promoter and is capable of influencing DNA methylation status at this 
region206. Another example is a cryptic unstable antisense paRNA of TY1 in 
Saccharomyces cerevisiae that mediates silencing of TY1 expression 207. It has also been 
speculated that long paRNAs could be a source for the formation of double-stranded RNAs 
with their overlapping counterparts giving rise to endo-siRNAs 208. 
 
1.4 PSEUDOGENES 
The term pseudogene was created on their discoveries in 1977209. To date, there are thought 
to be around 11.000 pseudogenes in the human genome thereof 876 that are transcribed210. In 
general, pseudogenes are described as duplicated genes that have lost their capacity to code 
for protein. It should however be stated that a recent proteomics study observed peptides 
being encoded by 107 pseudogenes211. It is, however, unknown if these peptides are being 
accidentally translated or if they have a physiological function. Due to the nature of 
pseudogenes they often retain high sequence homology to their coding parental gene210. Over 
time pseudogenes have accumulated mutations that cause premature stop codons or frame 
shift mutations that prevent them from being expressed. Although before thought of as “junk” 
DNA emerging evidence exists for their functional properties 141,209. Pseudogenes are 
classified according to how they are generated from their ancestral functional genes, and the 
main subgroups are:   
• Processed pseudogenes 
• Unprocessed pseudogenes 
• Unitary pseudogenes 
Processed pseudogenes are mRNAs that have been spontaneously reversed transcribed and 
randomly inserted back into the genome, often far from the parental gene (Figure 6). 
Processed pseudogenes lack introns, have poly-adenine features at the 3´end and are flanked 
by target site duplication. Processed pseudogenes lack a promoter and are therefore 
dependent upon the location of its insertion for becoming transcriptionally active. Vast 
majority of pseudogenes are processed pseudogenes212  and are thought to be a result of burst 
in retrotransposone activity in ancestral primates about 40 million years ago.  
Unprocessed pseudogenes are duplicated gene loci that often are inserted near the parental 
gene. This process occurs when cells in DNA replication make an extra copy of a gene locus 
(Figure 6). Duplicated pseudogenes can therefore bare parts or full replicas of parental genes 
including promoters, introns and exons213.  
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Unlike unprocessed and processed pseudogenes that arise from genomic insertion, unitary 
pseudogenes are genes that have lost their function and therefore do not have a functional 
parental gene in the genome. There could also be an argument for these genes gaining a new 
function210.  
 
Figure 6 Pseudogenization occurs through duplication or retrotransposition from mRNA consequently followed 
by mutations. Transcribed psedudogenes can act a competitive endogenous RNAs (modified from214). 
1.4.1 Pseudogenes as competitive endogenous RNA 
Recent data shows that pseudogenes can regulate their parent counterpart on the 
transcriptional level. The tumor suppressor gene PTEN has a pseudogene (PTENpg1, 
PTENp1, PTENψ) located on chromosome 9 that has high sequence homology with only 18 
nt mismatches throughout the sequence. The 3´UTR of PTENpg1 is about 1 kb shorter than 
that of PTEN. It possesses two regions, one with very high homology and another one with 
low homology to PTEN. Therefore, within the high homology region of PTENpg1 the PTEN-
targeting miR-17, miR-21, miR-214, miR-19 and miR-26 families have perfect matches in 
seed sequences, and some miRNAs are capable of repressing both PTEN and PTENpg1 
transcripts. Upregulation of the 3´UTR of PTENpg1 showed a de-repression of PTEN 
transcripts and protein levels, indicating that PTENpg1 can act as a decoy of competing 
miRNAs141(Figure 6). Interestingly, in the same study a similar observation was seen 
between the proto-oncogene KRAS and its pseudogene KRASP1141.  Further, PTEN deletions 
are a common event in human melanomas215 and partial or full deletions of PTENpg1 are 
found in 21% of melanoma tissues.  Nine out of 33 samples with PTENpg1 deletions showed 
reduced PTEN expression suggesting a competitive endogenous RNA (ceRNA) network 
between PTEN and PTENpg1216. Another study showed the PTENpg1 to be downregulated 
due to methylation in clear-cell renal cell carcinoma and overexpression of PTENpg1 reduces 
cell proliferation, invasion, tumor growth and metastasis217. In this study the pseudogene 
PTENpg1 served as a ceRNA to modulate PTEN expression by miR21 regulation. 
The proto-oncogene, BRAF has a pseudogene that is frequently overexpressed in various 
tumor types218,219 and ceRNA network between BRAF and its pseudogene in humans and in 
mice has been reported. Interestingly, overexpression of the BRAF pseudogene in mice, 
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Braf-rs1, causes aggressive malignancy resembling B-cell lymphoma while silencing of its 
human ortholog, BRAFP1 effected MAPK signaling and proliferation in human cancer 
cells220. 
The ceRNA network has also been proposed for lncRNA and mRNA that are thought to 
regulate each other221-223, whereas the lncRNAs can sequester miRNA away from mRNAs.  
But the ceRNA network has also received some critics. A recent study tried to address this by 
expressing varying amounts of a competitor RNA to the very abundant miR-122 (120.000 
molecules per hepatocyte). The results showed that about 150.000 miR-122 binding sites 
were needed in order to affect the expression of an endogenous mRNA, a target of miR-122 
224. However, the RNA expression levels are not even nearly close to generate this amount of 
binding sites. Another study showed that ceRNA network was not effective for highly 
expressed miRNAs; however, the ceRNA network could be fully functional in a 
physiological setting for the low expressed miRNA225.  
1.4.2 Antisense transcription from pseudogenes 
About 20% of pseudogenes have shown to have antisense transcript and vast majority of 
them are coming from duplicated pseudogenes. This phenomenon gives rise to the possibility 
for antisense transcripts to influence its parental gene in trans 226,227. In 1992, the first 
antisense transcript from a eukaryotic topoisomerase I (TOPI) pseudogene was discovered in 
humans. Although at that time the function of this antisense transcript was not described, it 
was speculated that antisense transcripts to a pseudogene would function through RNA:RNA 
duplex formation228 . Few years later another antisense transcript from the fibroblast growth 
factor receptor (FGFR) pseudogene in mouse was reported. The study confirmed the 
transcript to be tissue specific although they did not address its function229. Still to date, very 
few studies managed to reveal how these antisense transcripts function. Studies on antisense 
transcripts from the NOS and Oct4 pseudogenes are examples of these attempts. A 
pseudogene to the nitric oxide synthase (NOS) gene is found in the central nervous system of 
snails. This pseudogene has an antisense homology region to the parental gene and functions 
in trans by forming a RNA:RNA duplex, which leads to decreased translation of the NOS 
gene230. The pluripotency-associated factor Oct4 has six related pseudogenes (Oct4-pg1-
6)231.  One of those pseudogenes (Oct4-pg5) has an antisense transcript that negatively 
regulates Oct4-pg4 and Oct4-pg5. This antisense is thought to function by mediating 
epigenetic silencing at the Oct4 promoter209.  
1.4.3 Pseudogenes: source for endo-siRNA 
SiRNA can arise between two transcripts that share complementary regions. Pseudogenes 
share high homology with their parental genes providing a possible source for endo-siRNAs. 
Endo-siRNAs are common small RNA in plants and are known to be produced by RNA-
dependent RNA polymerase (RdRP) that catalyzes the replication of RNA from a RNA 
template. In mammals the existence and biogenesis of endo-siRNAs are obscure, however, 
there is evidence for their existence as mentioned here. Endo-siRNAs can be formed when a 
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spliced transcript from a protein coding gene forms a RNA duplex with an antisense 
transcript emitting from a pseudogenes or when pseudogenes have inverted repeats that bind 
to a transcript from the parental ancestral gene232. Another in vivo study on growing mouse 
oocytes found an endo-siRNA being regulated by the RNAi pathway, a unique way for 
pseudogenes to regulate mRNAs233.  
 
1.5 EPIGENETICS- A LNCRNA PERSPECTIVE 
Epigenetic modifications at gene promoters play a major role in creating discrepancy between 
tissues and individual cells. LncRNAs have been recognized as effectors of epigenetic 
changes at specific gene promoters. For epigenetic changes to take place at a gene promoter, 
an orchestrated effort of different components is vital. Here, the epigenetic modifications 
such as DNA methylation and histone modification will be discussed.  
DNA methylation  
CpG islands span a tiny fraction of the whole genome covering around 0.7% and are 
usually located in gene promoters234,235. DNA methylation is a biochemical modification of 
the DNA, where DNA methyltransferases catalyze the transfer of a methyl group (CH3) 
onto a carbon group located at the C5 position of the pyrimidine ring of cytosines and this 
occurs predominantly at CpG islands236,237. This reaction is catalyzed by a family of DNA 
methyltransferases identified as DNMT1, DNMT3a, DNMT3b and DNMT3L238.   
Unlike other family members, DNMT1 can identify hemi-methylated portion of newly 
replicated DNA and maintain the methylation status at specific gene loci. A study on 
methylation investigated RNA transcripts associated with DNMT1 and found frequent 
interaction between RNAs and DNMT1 at numerous gene loci. These DNMT1 bound 
RNAs are thought to evict DNMT1 from their site of expression. One example showed 
DNMT1 binding to a lncRNA called extra coding CEBPα (ecCEBPα) arising in the sense 
direction from the methylation-sensitive gene CEBPα, which prevented methylation of the 
CEBPα gene locus239. Interestingly, the DNA methylation levels were inversely correlated 
with ecCEBPα expression levels. Although there is uncertainty regarding the mechanism of 
RNA binding to proteins, the study suggests a stem-loop structure that could possibly 
facilitate the interaction between ecCEBPα and DNMT1239. In contrast to previous study 
lncRNAs can also keep DNMT1 at site. For example, the lncRNA Kcnq1ot1 interacts with 
DNMT1 in mice and mediates silencing of ubiquitously imprinted genes by binding to 
DNMT1 and keeping it in place for maintaining allele-specific methylation240.  Dum is 
another lncRNA that interacts with DNMT1 along with other DNMT family members. In 
skeletal myoblasts, Dum is upregulated in the differentiation process and effects in a cis 
action the expression of nearby genes by interacting with DNMT family members241. In 
order to address this more globally Merry et. al. did RNA immunoprecipitation (RIP) of 
DNMT1 and sequencing of associated RNAs revealed 148 lncRNA bound to DNMT1 in 
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HCT116 cells. Interestingly, only 31 mRNAs were pulled down indicating that DNMT1 
has increased affinity for lncRNA242.  
DNMT3a and DNMT3b are de novo methyltransferases243 that catalyze the transfer of a 
methyl group onto cytosine. There is also some new evidence that they can maintain 
methylation244. In spite of the importance of this enzyme there are still facades of DNMT3a 
that remains to be elucidated. In order to investigate the role of DNMT3a on transcriptional 
repression one study fused DNMT3a to Cas9 enzyme and targeted it to specific gene loci. 
Interestingly, this resulted in only moderate transcriptional repression245 and not strong 
gene silencing that normally is obtained upon DNMT3 binding to promoters. Possibly, 
DNMT3a needs to form a complex with other proteins in order to maximize its function. 
DNMT3a has been shown to bind to the DNA methyltransferase 3- like protein (DNMT3L) 
and the chromatin remodeling ATPase, LSH, that assist DNMT3a in enhancing its DNA 
affinity or activity246,247. In addition, PIWI proteins can recognize transposons that have 
escaped de novo methylation and this leads to recruitment of DNMT3a to transposons. 
Until recently it has been poorly understood how DNMT3a finds its way to promoters of 
differentially expressed genes. LncRNAs have been suggested to bind to and recruit 
DNMT3a to gene promoters and influence gene expression. For example; in the very 
intrinsic process of X chromosomal activation, the lncRNA Tsix recruits DNMT3a to the 
promoter of Xist, which leads to epigenetic silencing 151,248. In addition, the aforementioned 
lncRNA Dum has also been shown to interact with DNMT3a241.  
Histone modification  
Polycomb group proteins (PcG) function in two complexes, PRC1 and PRC2, which trigger 
histone modifications that subsequently lead to transcription silencing.  
Polycomb repressive complex 2 (PRC2) 
The PRC2 complex is conserved from Drosophila and causes mono-, di- or tri- methylation 
of histone 3 at lysine 27 (H3K27me3)249-251. The main players of the PRC2 complex are the 
following PcG components; enhancer of zeste 2 (EZH2) (or its homolog EZH1), suppressor 
of zeste 12 (SUZ12) and embryonic ectoderm development (EED).  EZH2 or EZH1 act as the 
catalytic subunit and SUZ12 - as the regulatory subunit of PRC2. In Drosophila, the PRC2 is 
recruited to the DNA by sequences called polycomb response elements (PRE)252 and this 
process is thought to occur independent of other proteins. The recruitment of PRC2 complex 
in humans however has been a matter of debate. Indeed, PRC2 complex binds predominantly 
to CpG islands but the DNA sequence itself can not directly recruit the complex and therefore 
the recruitment has to be mediated through other components. Transcription factors253, 
methyltransferases254 and lncRNAs150,170 have all been suggested as major players in this 
process. 
The lncRNA HOTAIR and the RepA element of Xist were the first lncRNA that were 
suggested to bind to and recruit PRC2 to the specific gene loci150,170.  In addition, a genome 
wide study showed that about 20% of all lincRNAs are bound to PRC2 complex171. Since 
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then there have been several reports showing interaction between lncRNA and the PRC2 
complex10,255. These studies have prompted further investigation on the connection between 
PRC2 and lncRNA.  
Although RNAs can physically bind to the PRC2 complex, this RNA:protein interaction is 
poorly understood. Recent studies have shown promiscuous binding of the PRC2 complex to 
RNAs. For example, EZH2 has been found to promiscuously bind to RNAs with 
submicromolar affinity in vitro 256 and the PRC2 complex can bind to nascent RNA transcript 
at nearly all active genes, possibly protecting the DNA from inappropriate PRC2 binding257. 
SUZ12 has also been shown to be capable of interacting with RNAs258,259.  Although the 
binding affinity between EZH2 and PRC2 is higher than of SUZ12, one study suggests that 
SUZ12 is the leading protein in establishing contact between PRC2 and RNAs257.   
Some studies have tried to establish in greater depth the physical interaction between PRC2 
and RNAs.  One such study showed that the PRC2 complex is more likely to bind to exon-
intron boundaries and to 3´UTRs. It has also been suggested that the PRC2 complex has a 
higher affinity for RNA motifs that include short repeats of consecutive guanines260 as well 
as to short hairpins structures within RNAs 150.  
The interaction between HOTAIR and PRC2 complex has been fairly well studied however 
there still remains some discrepancy in their relationship. A study showed that in spite of 
strong binding between HOTAIR and PRC2, that the transcriptional mediated silencing by 
HOTAIR could still be carried out without the PRC2 complex261. This study used artificial 
tethering of HOTAIR to chromatin and suggested the recruitment of PRC2 to be a 
consequence of gene silencing rather than a cause. HOTAIR can also bind to another 
repressive chromatin modifying complex (LSD1/coREST/REST) that catalysis 
demethylation of H3K4me2 173.   Therefore, a better fundamental understanding of the 
relationship of PRC2 and lncRNAs is needed.   
Polycomb repressive complex 1 (PRC1) 
The PRC1 complex is typically composed of Bmi1/Mel8, mPh1/2, Pc/Chromobox and 
RingA/B proteins. PRC1 is rather thought to maintain repressed chromatin but can also 
monoubiquitinate histone H2AK119 causing transcriptional silencing by inhibiting the 
elongation of RNA pol II262. The PRC1 complex can recognize trimethylation of H3K27, 
which surfs as a docking site for the PRC1 subunit, chromobox-domain. In addition, the 
PRC1 complex is also thought to interact with RNAs and the aforementioned antisense 
transcript ANRIL binds to CBX7 of the PRC1 complex and represses transcription163.  
Associations between DNA methylation and histone modification 
DNA methylation and histone modifications both contribute to gene silencing; however 
DNA methylation establishes more of a long term silencing while modification of histones 
can more easily be converted. In spite of fundamental differences in how these two 
pathways induce silencing they exhibit cross-talk where they can guide each other to 
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chromatin. It is unclear if this cross-talk happens through the modifications themselves or 
through the protein-protein interaction.   
EZH2 can facilitate DNMTs binding to promoters that are repressed by EZH2 and the 
presence of EZH2 is essential for DNMT methylation at these promoters254.  In addition, 
H3K27me3 enriched promoters in embryonic stem cells are more likely to be DNA 
methylated during differentiation and carcinogenesis than those that lack H3K27me3263-265. 
Also, other epigenetic complexes can influence and support each other’s functions. G9 and 
GLP are Histone H3 Lysine 9 methyltransferases that can mono- or di-methylate’s H3K9. 
G9a and GLP can physically interact and are thought to functionally interact with each 
other through a subunit of EZH2266. Taken together, histone modifications and DNA 
methylations seem to facilitate each other however the exact underlying mechanism needs 
to be elucidated.    
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AIMS OF THIS THESIS 
The overall aim of this thesis is to expand and deepen our understanding of the functional 
role of lncRNAs in molecular processes and to investigate their involvement in cancer, 
particularly in cutaneous malignant melanoma.  
Paper I:  
The aim of paper I was to untangle the regulation of expression of the tumor suppressor 
PTEN and the functional role of the PTEN pseudogene antisense transcript (PTENpg1 
asRNA) in this process.  
Paper II:  
The aim of paper II was to unravel the molecular mechanism of the recruitment of PTENpg1 
asRNA to the PTEN promoter by investigating the role of paRNA emitting from the 5´UTR 
of PTEN.  
Paper III:  
The aim of paper III was to explore the down regulation of PTEN expression and the 
involvement of PTENpg1 asRNA in the drug resistance in melanoma using vemurafenib-
resistant cell lines as well as investigation of PTENpg1 asRNA expression levels in melanoma 
patient samples. We also aimed to reveal the regulation of PTENpg1 asRNA by the 
transcription factor CEBPβ. 
Paper IV:  
The aim of paper IV was to investigate the role of CEBPβ-AS in the regulation of CEBPβ 
expression and consequently in drug sensitivity in vemurafenib-resistant melanoma cell lines.  
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RESULTS AND DISCUSSIONS 
1.6 PAPER I 
A pseudogene long-noncoding-RNA network regulates PTEN transcription and translation in 
human cells 
1.6.1 Rational  
Pseudogenes were once thought as genomic fossil or “junk” DNA; however in recent years 
they are gaining attention for being functional141,220. For example, the PTEN pseudogene 
(PTENpg1, PTENp1, PTENψ) has been shown to function as a mircoRNA sponge that soaks 
up miRNAs and sequesters them away from their targets141. Pseudogenes can also be a source 
for antisense transcription and these overlapping transcripts often share sequence 
complementarity to their protein-coding counterparts. Although it has been clear that 
antisense transcription was emitting from pseudogenes226, functional studies of this 
phenomenon are rare but it has been reported that an asRNA emitting from the Oct4-
pseudogene 5 affects the expression levels of its protein coding counterpart, Oct4209. Here we 
aimed to investigate an antisense transcript emitting from the PTENpg1 and its effect on the 
tumor suppressor gene PTEN. In addition, we set out to untangle the distinctive roles of 
various isoforms of PTENpg1 asRNA.  
1.6.2 Main findings and discussions 
The PTENpg1 encodes an antisense RNA 
Initially, we observed one aligned EST (Expressed sequence tags) designated as BX374997 
in the UCSC (University of California, Santa Cruz) genome browser. This EST was located 
upstream of the PTENpg1 transcription start site (TSS), which encouraged us to look further 
into the possibility of an antisense transcription emitting from the PTENpg1 locus. 
Additionally, the ENCODE ChIP–sequencing data showed enrichment of the active 
transcriptional histone mark H3K4me3 and the RNA pol II at two different locations within 
the PTENpg1 locus, indicating two different TSS that overlap with the PTENpg1 sense 
promoter. To experimentally validate these indications from the UCSC genome browser we 
performed 5´RACE and designed primer walks. This analysis indicated two TSS giving rise 
to at least two different isoforms that we designated as α and β. Fractionation analysis showed 
both of the spliced PTENpg1 asRNA α and β isoforms to be found predominantly in the 
cytoplasm while an unspliced PTENpg1 asRNA was expressed solely in the nucleus. We 
attempted to further untangle the diversity of isoforms of PTENpg1 asRNA using Northern 
blotting, however, without any success. This was possibly due to the fact that the antisense 
transcript is composed of two segments: one with high sequence complementarity to the 
PTEN gene and the other - with highly repetitive elements (mostly LINE repeats) making it 
difficult to design specific probes.   
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PTENpg1 asRNA α recruits epigenetic modifiers to silence PTEN transcription 
We investigated the expression levels of the discovered transcripts in a panel of human cell 
lines and, interestingly, their expression inversely correlated to the PTEN mRNA expression 
levels. This prompted us to explore if knockdown of PTENpg1 asRNA α with siRNA or 
shRNA would affect the expression of PTEN. Indeed, PTEN levels were elevated after 
PTENpg1 asRNA knockdowns, and this induction was seen already at the pre-mRNA levels 
indicating an effect on transcription. This was further supported by nuclear run-on assay and 
ChIP for RNA pol II binding at the PTEN promoter. Next, we fluorinated and biotin-linked 
the PTENpg1 asRNA in order to investigate if the PTENpg1 asRNA binds to the PTEN 
promoter. Pull-down of the biotin-linked transcript showed that PTENpg1 asRNA localizes to 
the PTEN promoter. Further, we knocked down EZH2 and DNMT3a and observed induced 
expression of PTEN, while simultaneous knockdown of EZH2 and PTENpg1 asRNA α 
showed no additive effect, indicating that these factors work in the same pathway. RIP 
showed an existing interaction between the PTENpg1 asRNA and DNMT3a supporting the 
hypothesis that they form a RNA-protein complex together. In order to investigate if the 
PTENpg1 asRNA α recruits EZH2 and DNMT3a to the PTEN promoter, ChIP analysis was 
carried out, and we observed a decreased enrichment of EZH2 and H3K27me3 at the PTEN 
promoter after depletion of PTENpg1 asRNA α. Further, siRNA depletion of PTENpg1 
asRNA α resulted in induced protein levels of PTEN and concomitant downregulation of the 
pAKT, and therefore inhibition of the PI3K/AKT pathway. This also resulted in reduced 
levels of the cell cycle regulator p21, and FACS analysis showed a G0-G1 arrest after 
PTENpg1 asRNA α depletion.  
Although studies have reported lncRNAs to guide DNMT3a to gene loci, our study was the 
first to our knowledge that demonstrated an interaction between lncRNAs and DNMT3a. 
Since our study was published, there have been at least two other publication showing an 
interaction between lncRNAs and DNMT3a241,267.  
Taken together, PTENpg1 asRNA α recruits the epigenetic modifying proteins, EZH2 and 
DNMT3a to the promoter of PTEN, which consequently leads to epigenetic silencing of the 
tumor suppressor. This is in agreement with accumulating data on the interaction of ncRNAs 
with epigenetic modifiers 163,209,254,268. In addition, these results add to the understanding of 
possible functional roles of pseudogene transcripts in transcriptional silencing.  
PTENpg1 asRNA β stabilizes its sense transcript through RNA:RNA interaction 
Sense-antisense transcripts have shown to form a partial duplex that stabilizes the 
transcripts168,269 and therefore we sought out to explore if the PTENpg1 asRNA could stabilize 
its sense transcript through such interactions. We observed that the PTENpg1 sense transcript 
lacks a poly-A tail; poly-A tailing of RNA transcripts usually leads to an increased RNA 
stability and assists in shuttling of RNAs from the nucleus to the cytoplasm 270-272. By 
blocking transcription with Actinomycin D, however, similar stability was found for the 
polyA-tail lacking PTENpg1 sense, as well as for PTEN and the PTENpg1 asRNA. When we 
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used endoribonuclease RNase-A to digest single stranded RNA, we observed an overlapping 
region of the transcripts that was not degraded clearly pointing at the formation of duplexes. 
We then used antisense phosphorothioate oligodeoxynucleotides (ODNs) and shRNA to 
interfere with the interaction between the PTENpg1 sense and asRNA β that both resulted in a 
decreased expression of the sense transcript. Interestingly, this also led to decreased 
expression of PTEN at the RNA as well as at the protein level, an observation that is in line 
with the previously published ceRNA network141. Although the PTENpg1 asRNA α transcript 
shares a longer sequence overlap than PTENpg1 asRNA β with PTENpg1 sense we did not 
observe any binding between PTENpg1 sense and asRNA α. Interestingly, the WRAP53 
asRNA (see section 1.3.2) has been reported to have at least three different isoforms, among 
those only one forming an RNA:RNA interaction with its sense counterpart, p53168.  A 
possible explanation is that some isoforms might form specific secondary structures or bind 
to proteins that block potential interactions. Further studies are needed in order to understand 
this phenomenon in more details.  
Taken together, PTENpg1 asRNA β stabilizes the PTENpg1 sense transcript through an 
RNA:RNA interaction and our findings also suggest that PTENpg1 asRNA β is involved in 
export of the PTENpg1 sense transcript where it serves as miRNA sponge. Unlike its α 
transcript, PTENpg1 asRNA β functions at the post-transcriptional level.  
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1.7 PAPER II 
The molecular dynamics of long noncoding RNA control of transcription in PTEN and its 
pseudogene 
1.7.1 Rational 
Subtle changes of PTEN alter cancer susceptibility61 and it is therefore vital for the gene to be 
under tight regulation in order to keep adequate expression levels. The aforementioned 
PTENpg1 asRNA network fine-tunes PTEN expression by recruitment of chromatin 
remodeling proteins to the PTEN promoter. However, it is poorly understood how lncRNAs 
that are functioning in trans can find their way to gene promoters. Previously, small 
transiently transfected RNAs directed towards promoter associated RNAs have been shown 
to mediate transcriptional regulation of protein coding genes208,273. Here, we set out to 
investigate if the PTEN locus encodes for such promoter associated RNAs and whether such 
transcripts are involved in recruitment of PTENpg1 asRNA α to the promoter of PTEN, 
possibly through RNA:RNA interactions.  
1.7.2 Main findings and discussions 
Detection of PTEN promoter-associated RNA/5´UTR transcript 
In the UCSC genome database, ESTs were found to span the PTEN 5´UTR. We used strand-
specific directional reverse transcription (RT) PCR to detect if these transcripts exist in 
cellular settings. Indeed, a 5´UTR transcript spanning this region was detected; it was, 
however, difficult to further characterize it due to its extensive overlap with other PTEN 
associated transcripts. In order to explore the functional role of this transcript we designed a 
single-stranded antisense ODNs targeting the PTEN paRNA/5´UTR transcript. ODNs are 
single-stranded DNA oligos with the capacity to hybridize to the targeted RNA in a 
sequence-specific manner and sterically interfere with the targeted transcript. The ODNs used 
in this study are phosphorothioate ODNs, which are resistant to nucleases. We designed 
multiple phosphorothioate ODNs and picked one, ODN2, with the capacity to interfere with 
paRNA/5´UTR. Interestingly, a biotin-labeled ODN2 also managed to pull-down PTEN-
5’UTR associated transcripts, including the full length of PTEN mRNA. 
The PTEN paRNA/5´UTR transcript interacts with the PTENpg1 as RNA network  
ODN2 inhibition of the PTEN paRNA/5´UTR transcript resulted in less binding of DNMT3a 
at the PTEN promoter and consequently less CpG methylation, indicating a role for the PTEN 
paRNA/5´UTR transcript in the recruitment of DNMT3a to the PTEN promoter. These 
observations prompted us to further investigate if the PTEN paRNA/5´UTR transcript 
interacts with the PTENpg1 asRNA network, previously shown to mediate recruitment of 
DNMT3a to the PTEN promoter (see paper I). We initially immunoprecipitated DNMT3a 
and discovered that both the PTENpg1 asRNA α exon 1 and the PTEN paRNA/5´UTR 
transcript could bind to DNMT3a, suggesting that these RNA transcripts could interact by 
forming RNA:RNA duplexes. To address this more specifically, HEK293 cells were co-
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transfected with biotin-labeled PTENpg1 asRNA α transcript and ODN2. Pull-down of the 
biotinylated RNA showed less binding to PTEN paRNA/5´UTR transcript after ODN2 
transfection, supporting that ODN2 indeed interfered with an interaction between 
paRNA/5´UTR and PTENpg1 asRNA. In addition, the interaction was stable upon RNase A 
treatment, which predominantly targets single-stranded RNA structures, further suggesting 
the presence of RNA:RNA interactions. 
Next, we set out to investigate the binding between PTENpg1 asRNA α and paRNA/5´UTR 
in more detail. To this end, various truncations of PTENpg1 asRNA α exon 1 were labeled 
with biotin and transfected into HEK293 cells. Again the biotin-labeled transcripts were 
pulled down and we observed binding to the PTEN promoter by two variants, F4R1 and 
F5R2, and the full-length transcript. Strikingly, only the F4R1 variant and the full-length 
PTENpg1 asRNA α exon 1 transcripts were capable of directing DNMT3a to the PTEN 
promoter while this capacity was lost for the F5R2 transcript.  
Analyses of secondary RNA structures suggested that both the F4R1 variant and PTENpg1 
asRNA α exon 1 have a major loop structure. We hypothesized that this loop structure could 
be important for the recruitment of DNMT3a to the PTEN promoter and therefore generated 
multiple truncations of this loop. Indeed, the truncations lead to the inability to bind to PTEN 
promoter indicating that the loop structure is necessary for the PTEN promoter targeting. 
Interestingly, the sequence of the loop structure maps to a locus where we observed high 
levels of DNMT3a and PTENpg1 asRNA α.  
Taken together, the PTEN paRNA/5´UTR transcript binds and assists the PTENpg1 asRNA α 
exon 1 transcript in recruiting DNMT3a to the promoter of PTEN, which causes epigenetic 
silencing of PTEN. The function of PTEN paRNA/5´UTR transcript in epigenetic silencing of 
the PTEN promoter adds to the regulatory layers of the tumor suppressor. The PTEN 
paRNA/5´UTR transcript is an example of the variety of transcripts that can originate from 
the same promoter and one of the diverse functions they are capable to carry out. Most 
importantly, our studies on PTEN illustrate the presence of multiple functional non-coding 
RNAs, long as well as short, with the capacity to regulate the same gene. 
Interestingly, this study suggests the existence of a major loop structure of the PTENpg1 
asRNA transcript important for its functional role; however, more studies will be needed in 
order to fully understand the structural interaction between the PTEN promoter and PTEN 
associated transcripts, as well as PTENpg1 asRNA and DNMT3a. For example, are there 
specific nucleotide sequences within the loop structure that are important for the recruitment 
of DNMT3a or is it just the loop structure itself? Further, is it the stem and/or the loop that 
maintains the function and how is the localization of PTENpg1 asRNA coordinated with the 
recruitment of DNMT3a?  
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1.8 PAPER III 
PTENpg1 antisense RNA mediates PTEN suppression in vemurafenib resistance and predicts 
clinical outcome in melanoma patients 
1.8.1 Rational  
Although BRAFV600E inhibitors (e.g. vemurafenib) improve survival rates for cutaneous 
melanoma patients, almost all patients will eventually develop drug resistance. Reduced 
PTEN expression, e.g. through epigenetic inactivation, has been suggested to be involved in 
the development of melanoma and also to contribute to vemurafenib resistance68,99,274. We 
therefore speculated that the PTENpg1 asRNA network could mediate suppression of PTEN 
upon the development of resistance to vemurafenib and possibly also be involved in the 
development of melanoma. 
1.8.2 Main findings and discussions 
PTENpg1 asRNA expression is induced in vemurafenib resistant A375 melanoma cell lines 
In order to investigate the PTENpg1 asRNA network we produced vemurafenib-resistant 
melanoma cell lines by culturing the melanoma cell line A375 at increasing doses of 
vemurafenib/PLX47020 for extended period of time. Next, we measured PTEN and 
PTENpg1 asRNA expression to see if the drug-resistant melanoma cell lines had acquired 
changes in their expression levels. All resistant cell lines (A375 PR1, A375 PR3 and A375 
PR4) showed upregulation of the PTENpg1 asRNA and sense transcripts, and downregulation 
of PTEN levels. PTENpg1 sense has previously been shown to sequester miRNA away from 
PTEN mRNAs141, and we therefore measured the PTEN mRNA and protein level expression. 
Strikingly, we did not observe the expected effect from the miRNA sponging activity, which 
would be manifested by an increased expression of PTEN, but instead - suppression of PTEN 
in all resistant cell lines. These data therefore suggest that PTENpg1 asRNA is the dominant 
regulator of PTEN in this model system. 
Next, we more specifically investigated which PTENpg1 asRNA isoform was being induced 
in the resistant cell lines. We predominantly observed induced expression of the PTENpg1 
asRNA α isoform in the A375 PR1 cell line and the transcript was also specifically enriched 
in the nuclear fraction. We next investigated if suppression of PTEN is a reversible process 
and if knockdown of PTENpg1 asRNA α could reactivate PTEN expression. We designed 
gapmer antisense oligonucleotides (ASO) that specifically target the nuclear pool of 
PTENpg1 asRNA α transcripts and indeed observed that knockdown of PTENpg1 asRNA α 
induced PTEN expression in the resistant cell lines; strikingly, this was not the case in the 
sensitive cells. 
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EZH2 and DNMT3a mediate epigenetic silencing of the PTEN promoter in A375 
vemurafenib-resistant cell lines 
These observations motivated us to further investigate if epigenetic silencing caused low 
PTEN mRNA and protein levels in A375 PR1. We used the McrBc enzyme that cleaves 
methylated DNA at PumCG sequence elements to assess DNA methylation at the PTEN 
promoter in the A375 and A375 PR1 cell lines. We observed increased enzymatic digestion 
at the PTEN promoter in the A375 PR1 cell line compared to the A375 cell line thus 
indicating enrichment of methylated DNA. Further, knockdown of EZH2 and DNMT3a 
caused upregulation of PTEN in the A375 PR1 resistant cells, while not affecting PTEN in 
the sensitive cells. These results indicate that epigenetic silencing of the PTEN promoter in 
A375 PR1 cell line is mediated through EZH2 and DNMT3a. The histone methyltransferase 
EZH2 is a subunit of the PRC2 complex that mediates tri-methylation on histone 3 lysine 27 
and has also been reported to interact with DNMT3a, thus bridging chromatin remodeling 
and DNA methylation together254. Therefore, we pulled down EZH2 and its downstream 
target H3K27me3 and found both to be enriched at PTEN promoter in A375 PR1 resistant 
cell lines. In addition, we pulled down EZH2 and DNMT3a and observed binding to 
PTENpg1 asRNA.   
This allowed us to propose a model for epigenetic silencing of PTEN in the vemurafenib-
resistant A375 melanoma cell line caused by PTENpg1 asRNA α that recruits epigenetic 
modifying proteins, EZH2 and DNMT3a, to silence PTEN transcription. 
Interestingly, the expression of PTENpg1 asRNA and PTENpg1 sense was concordantly 
upregulated in the resistant A375 cell lines. However, we observed a negative correlation 
between the PTENpg1 asRNA and PTEN, which indicates an epigenetic regulation of PTEN 
instead of a positive correlation that would be expected from a ceRNA network. One could 
speculate that equimolar concentrations of all components of the PTENpg1 ceRNA network 
are necessary to observe the effect; alternatively, very low expression of PTENpg1 asRNA are 
sufficient to carry out epigenetic silencing at the PTEN promoter while higher expressions of 
PTENp1 sense, than seen in the A375 resistant cell lines, is needed to sponge away miRNAs.  
The transcription factor C/EBPβ induces transcription of PTENpg1 asRNA α in vemurafenib-
resistant A375 cell line.  
In order to investigate the underlying mechanisms to induction of PTENpg1 asRNA α we set 
out to identify transcription factors potentially regulating expression of this locus. ChIP data 
from the ENCODE project showed strong binding of the transcription factor C/EBPβ 
upstream from the PTENpg1 asRNA α transcriptional start site. C/EBPβ was confirmed to be 
upregulated in the A375 PR1 cell line compared to A375 cell line, and knockdown of 
C/EBPβ caused downregulation of PTENpg1 asRNA α and, consequently, induced expression 
of PTEN. Interestingly, knockdown of C/EBPβ did not appear to reduce the expression of 
PTENpg1 sense. In addition, C/EBPβ was enriched at the PTENpg1 asRNA promoter in the 
resistant A375 PR1 compared to the sensitive A375 cell lines. Taken together, C/EBPβ is 
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upregulated in the A375 PR1 cell line and appears to be an important regulator of PTENpg1 
asRNA. Thus, this is the first TF identified regulating this locus, and it appears to act on a 
strand-specific level (on the antisense strand). We speculate that C/EBPβ is binding to the 
consensus sequence GTTGCGCAAT, this sequence is not found within the matching region 
of PTEN (~70 kb downstream from the PTEN TSS). In line with this, there is no indication 
from the ENCODE ChIP sequencing data that C/EBPβ could have binding sites at this 
position on PTEN or of a transcript emitting from this locus. Further, the nucleotides that 
make up the consensus sequence for this TF in the PTEN pseudogene are located on separate 
exons in PTEN, suggesting that during pseudogenization the PTEN pseudogene has acquired 
a regulatory sequence that is not found in the DNA of its parental gene.  
  
Increased cell death upon targeting of the PTENpg1 asRNA α network in vemurefenib-
resistant melanoma cell lines and PTENpg1 asRNA α as a potential biomarker 
Next, we set out to investigate if disruption of the PTENpg1 asRNA network could re-
sensitize vemurafenib-resistant A375 melanoma cell lines to vemurafenib through 
reactivation of PTEN, and a consequently suppressed PI3K/AKT survival pathway. 
Simultaneous knockdown of EZH2 and DNMT3a induced cell death in the resistant A375 
cell lines when combined with vemurafenib treatment. In line with this, knockdown of 
C/EBPβ as well as PTENpg1 asRNA also resulted in increased cell death upon vemurafenib 
treatment in A375 resistant cell lines. These results encouraged us to further investigate the 
clinical impact of PTENpg1 asRNA in melanoma patients. To this end, we used two different 
cohorts of stage III melanoma patients, and in both cohorts, we determined PTENpg1 asRNA 
expression in lymph node metastases by RT-qPCR. The first cohort patients were further 
divided into groups with long or short overall survival. Interestingly, patients with high 
PTENpg1 asRNA expression showed shorter survival. In the second cohort we divided the 
groups according to high or low expression of PTENpg1 asRNA. The survival plot showed a 
significant difference in the overall survival of melanoma patients between groups with high 
or low PTENpg1 asRNA expression.  
Here we described a novel role for the PTENpg1 asRNA in vemurafenib resistance in 
melanoma cell lines. DNMT3a and EZH2 were enriched at the PTEN promoter in the 
vemurafenib-resistant A375 cell lines. We observed interaction of these proteins with 
PTENpg1 asRNA, and propose that the PTENpg1 asRNA is mediating the recruitment of 
EZH2 and DNMT3a causing tri-methylation on lysine K27 on Histone 3 and DNA 
methylation of the PTEN promoter. Taken together, experimental manipulation of the 
PTENpg1 asRNA network can re-sensitize resistant A375 melanoma cell lines to vemurafenib 
treatment and manipulation of the PTENpg1 asRNA network may provide us with a 
therapeutic tool to de-repress PTEN and consequently inhibit the PI3K/AKT pathway. 
Moreover, the levels of PTENpg1 asRNA can represent a potential predictive biomarker for 
cutaneous malignant melanoma patients.   
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1.9 PAPER IV 
C/EBPβ-AS inhibits transcription of C/EBPβ through a negative feedback loop 
1.9.1 Rational  
Transcription factors have been extensively studied as important regulators of genes’ activity 
and the dynamic mechanism of their transcriptional regulation is of a great interest. C/EBPβ 
is a versatile transcription factor that regulates multicellular functions, and deregulation of 
this transcription factor has been implicated in various types of cancer103, 124, 121, 119. In paper 
III we found C/EBPβ to be a transcriptional regulator of PTENpg1 asRNA. This prompted us 
to investigate the involvement of C/EBPβ in cancer development by using the Cancer 
Genome Atlas (TCGA) dataset and further, what dictates the transcriptional expression of 
C/EBPβ. Previously, antisense transcripts have been shown to transcriptionally regulate their 
sense counter parts149,156,157 and therefore we sought out to investigate if the annotated 
antisense RNA transcript of C/EBPβ could regulate its transcription.  
1.9.2 Main findings and discussions 
Expression patterns of C/EBPβ and C/EBPβ-AS in human tumors and relation to overall 
survival  
In order to investigate the association between C/EBPβ and C/EBPβ-AS we took advantage 
of TCGA database. We found that the expression of the two transcripts showed moderate or 
strong positive correlation to each other in 32/33 cancer types including melanoma. 
Furthermore, C/EBPβ and C/EBPβ-AS expression showed some correlations to patient´s 
survival in various types of cancer. This correlation was, however, not consistent. In some 
cases it was the high expression while in other cancer types - it was the low expression that 
correlated to worse prognosis. In addition, we found that high C/EBPβ-AS expression 
correlated to a better prognosis in melanoma patients.  
The yin and yang of C/EBPβ regulation 
We noticed in the ChIP-seq data from ENCODE that C/EBPβ is enriched at both C/EBPβ-AS 
and C/EBPβ promoters suggesting that it should regulate both transcripts. Therefore, we 
explored if knockdown of C/EBPβ would affect transcription of C/EBPβ-AS. Indeed, 
knockdown of C/EBPβ showed downregulation of C/EBPβ-AS, in line with the observed 
positive correlation between C/EBPβ-AS and C/EBPβ expression in human tumors.  
We further set out to characterize C/EBPβ-AS and showed the transcript to be a 
polyadenylated RNA that localized both in the cytoplasm and in the nucleus. We decided to 
investigate its nuclear function in more detail, such as whether C/EBPβ-AS could be a 
transcriptional regulator of C/EBPβ. We designed siRNAs to knockdown C/EBPβ-AS 
expression. Upon knockdown of C/EBPβ-AS, we observed upregulation of C/EBPβ mRNA 
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and protein expression in the majority of cell lines. This was in contrast to our expectations, 
since we had observed concordant and positive correlation between C/EBPβ-AS and C/EBPβ 
in human tumors.   
In order to understand the negative regulation of C/EBPβ by C/EBPβ-AS, we investigated if 
C/EBPβ-AS expression could induce epigenetic changes at the C/EBPβ promoter. We 
knocked down C/EBPβ-AS and, to our surprise, observed an enrichment of EZH2 and 
H3K27me3 at the C/EBPβ promoter. Further, we used the McrBc enzyme that specifically 
cuts methylated DNA and observed more DNA methylation at the C/EBPβ promoter upon 
silencing of C/EBPβ-AS. Attraction of methyltransferases to the promoters, histone 
methylation and the methylated DNA are usually associated with gene silencing. However 
emerging recent data provide evidence that some specific gene loci can be activated upon 
DNA methylation111-113. Interestingly and in line with latter observation, C/EBPβ has been 
shown to bind more strongly to methylated sequences leading to increased gene activity114,115. 
Therefore, this TF may actually be attracted to methylated regions to activate gene 
transcription (its own, in this case). C/EBPβ-AS, on the other hand, may fine-tune the activity 
of C/EBPβ promoter in that low levels of C/EBPβ-AS allow for the activation of C/EBPβ 
promoter while its increased expression may attract and sequester epigenetic factors away 
from the promoter.  
Resensitization of vemurafenib-resistant melanoma cell lines   
In paper III, we reported that suppression of C/EBPβ could re-sensitize the A375 PR1 cell 
line to vemurafenib treatment, and therefore we set out to investigate if manipulating 
C/EBPβ-AS levels would affect sensitivity towards vemurafenib treatment. We knocked 
down C/EBPβ-AS in vemurafenib-sensitive and -resistant A375 as well as in dabrafenib-
sensitive and -resistant MNT1 cell lines, and treated the cells with two different 
concentrations of vemurafenib. All cell lines showed increased sensitivity towards 
vemurafenib treatment after C/EBPβ-AS knockdown. This was an unexpected finding since a 
decrease in C/EBPβ-AS would lead to the activation of C/EBPβ. However, there are examples 
in the literature when overexpression of C/EBPβ has been shown to cause reduced cell 
growth and increased cell death. For example the overexpression of C/EBPβ LIP isoform has 
shown to induce cell death in mouse melanoma cells275, and C/EBPβ overexpression in 
prostate cancer cells has been shown to reduce cell growth after doxycycline treatment276.		
The observed sensitization to vemurafenib treatment after C/EBPβ-AS knockdown promoted 
us to further look into how C/EBPβ-AS affects the two major pathways that contribute to 
vemurefenib resistance: the PI3K/AKT and the MAPK pathways. Interestingly, our results 
showed that C/EBPβ-AS knockdown induced p-AKT (T308 and S473). This is in line with 
our data on C/EBPβ being a transcriptional activator of PTENps1 asRNA, a negative 
regulator of PTEN. This is also in agreement with a study suggesting C/EBPβ to be an 
activator of the PI3K/AKT pathway through the IL-8 cytokine276. It is, however, well 
established that activation of the PI3K/AKT and MAPK signaling pathways would promote 
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cell proliferation and survival. It remains therefore to further reveal the molecular 
mechanisms of sensitization to vemurafenib by C/EBPβ-AS knockdown. Activation of some 
pathways, e.g. EGFR that also activate the PI3K/AKT pathway, can under some conditions 
cause cell death independent of the PI3K/AKT pathway277. Therefore, the hypothesis is that 
activation of other proteins through C/EBPβ is important to trigger increased vemurafenib 
sensitivity upon C/EBPβ-AS knockdown. Alternatively, manipulation of C/EBPβ-AS levels 
affects other pathways by acting in trans on other genes’ promoters. 
Taken together, we characterized a novel transcript, C/EBPβ-AS that can be induced by and 
fine-tune the expression of C/EBPβ. Manipulation of C/EBPβ levels can clearly reverse the 
resistance towards vemurafenib in melanoma cell lines, and so does knockdown of C/EBPβ-
AS. However, the exact mechanism behind this remains unclear. We have also revealed an 
unusual affinity of C/EBPβ to its own methylated promoter in that levels of C/EBPβ-AS play 
a crucial role in mediating these epigenetic changes. 
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CONCLUDING REMARKS 
The results of the work included in this thesis revealed novel regulatory mechanisms and the 
role of ncRNAs in cancer. The main findings are:  
  
• An antisense RNA emitting from the PTEN pseudogene, PTENpg1 asRNA, can 
transcriptionally and post-transcriptionally regulate the tumor suppressor gene PTEN.   
 
• PTENpg1 asRNA α recruits epigenetic modifying proteins to the PTEN promoter.  
 
• PTENpg1 asRNA β binds to and stabilizes the PTENpg1 sense.  
 
• A PTEN 5´UTR/promoter associated transcripts assist the PTENpg1 asRNA α 
transcript to the PTEN promoter mediating recruitment of DNMT3a and consequently 
leads to epigenetic silencing of the promoter.  
 
• The PTENpg1 asRNA contributes to vemurafenib resistance by mediating epigenetic 
silencing of PTEN in melanoma cells.  
 
• PTENpg1 asRNA is a potential biomarker in melanoma patients. 
 
• The transcription factor C/EBPβ the regulates PTENpg1 asRNA.  
 
• C/EBPβ is a major regulator of its own and its antisense transcript, C/EBPβ-AS. 
C/EBPβ-AS inhibits C/EBPβs positive feedback-loop by mediating epigenetic 
changes at the C/EBPβ promoter.  
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